Clood

/ Unipharm

One tablet a day.
See prescribing information for full details.

For the prevention of atherothrombotic events as follows:Recent MI, recent stroke or established peripheral arterial disease: Patients suffering from MI (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For patients with a history of recent MI, recent stroke, or established peripheral arterial disease, treatment has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute MI, in combination with ASA in medicdbally treated patients eligible for thrombolytic therapy.

Hypersensitivity to the active substance or to any of the excipients of the medicinal product. Severe liver impairment. Active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Lactation.

Safety and efficacy in subjects below the age of 18 have not been established. There is no experience in children.
Renal impairment: Therapeutic experience is limited in patients with renal impairment.
Hepatic impairment: Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.
Contains lactose and hydrogenated castor oil.
Pregnancy and lactation: As a precautionary measure, should not be used during pregnancy.

Eye bleeding (conjunctival, ocular, retinal), epistaxis. Gastrointestinal hemorrhage, diarrhea, abdominal pain, dyspepsia. Bruising, bleeding at puncture site.

Warfarin, acetylsalicylic acid (ASA), heparin, thrombolytics, NSAIDs.